A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03375164 |
Recruitment Status :
Completed
First Posted : December 15, 2017
Last Update Posted : August 1, 2023
|
Sponsor:
Sarepta Therapeutics, Inc.
Information provided by (Responsible Party):
Sarepta Therapeutics, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | April 25, 2023 |
Actual Study Completion Date : | April 25, 2023 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
April 24, 2024 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):